How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

Last year
R&D

Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Last year
R&D
Cell/Gene Tx

Har­poon, Ali­gos an­nounce PIPEs; NAYA's all-stock deal; In­vea to go pub­lic

Last year
News Briefing

Roivant CEO urges pa­tience on fu­ture af­ter $7B+ sale to Roche

Last year
Deals
Pharma

As­traZeneca, Dai­ichi Sankyo still need key over­all sur­vival re­sults on TROP2 ADC in breast, lung can­cer: #ES­MO23

Last year
R&D
Pharma

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Last year
R&D

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
Deals
R&D

In­di­v­ior agrees to pay out $385M to end years­long Sub­ox­one lit­i­ga­tion and ac­cu­sa­tions it pre­vent­ed gener­ic ...

Last year
Pharma
Law

Mer­ck ax­es two of nine AD­Cs in pact with Kelun-Biotech

Last year
Deals
China

Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

Last year
R&D

Ear­ly da­ta on Dai­ichi Sankyo’s Mer­ck-part­nered ADC; As­traZeneca’s Da­to-Dxd com­bo; more from Seagen: #ES­MO23 ...

Last year
R&D
Pharma

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Last year
Deals
Pharma

Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

Last year
R&D
Pharma

Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

Last year
R&D
Pharma

CAR­GO Ther­a­peu­tics heads to Nas­daq in first CAR-T cell ther­a­py IPO pitch of 2023

Last year
Financing
Startups

Ic­ahn law­suit calls for mil­lions in dam­ages, re­moval of Il­lu­mi­na board mem­bers

Last year
Law

Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in ...

Last year
Weekly

Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Last year
R&D
Pharma

A first for the Eu­ro­pean Com­mis­sion: Five phar­ma com­pa­nies fined $14M for API price fix­ing

Last year
Pharma

Pfiz­er wins first US ap­proval for pen­tava­lent meningo­coc­cal vac­cine 

Last year
Pharma
FDA+

House Re­pub­li­cans threat­en sub­poe­na over de­tails of NIH mpox re­search

Last year
FDA+

RWD and RWE are not the same: FDA lead­ers dis­pel com­mon mis­con­cep­tions in new pa­per

Last year
Pharma
FDA+

Nec­tar Life­sciences hit with un­ti­tled let­ter over re­peat GMP is­sues at an­timi­cro­bial site

Last year
FDA+
Manufacturing

Eli Lil­ly cracks down on im­porters and dis­trib­u­tors of com­pound­ed Moun­jaro

Last year
Pharma
First page Previous page 259260261262263264265 Next page Last page
A service from the Financial Times